Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 363

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

Open access
Ryken, Timothy C., McDermott, Michael, Robinson, Paula D., Ammirati, Mario, Andrews, David W., Asher, Anthony L., Burri, Stuart H., Cobbs, Charles S., Gaspar, Laurie E., Kondziolka, Douglas, Linskey, Mark E., Loeffler, Jay S., Mehta, Minesh P., Mikkelsen, Tom, Olson, Jeffrey J., Paleologos, Nina A., Patchell, Roy A., Kalkanis, Steven N.·2010·Journal of Neuro-Oncology

Abstract

QUESTION: Do steroids improve neurologic symptoms in patients with metastatic brain tumors compared to no treatment? If steroids are given, what dose should be used? Comparisons include: (1) steroid therapy versus none. (2) comparison of different doses of steroid therapy. TARGET POPULATION: These recommendations apply to adults diagnosed with brain metastases. RECOMMENDATIONS: Steroid therapy versus no steroid therapy Asymptomatic brain metastases patients without mass effect Insufficient evidence exists to make a treatment recommendation for this clinical scenario. Brain metastases patients with mild symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. It is recommended for patients who are symptomatic from metastatic disease to the brain that a starting dose of 4-8 mg/day of dexamethasone be considered. Brain metastases patients with moderate to severe symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. If patients exhibit severe symptoms consistent with increased intracranial pressure, it is recommended that higher doses such as 16 mg/day or more be considered. Choice of Steroid Level 3 If corticosteroids are given, dexamethasone is the best drug choice given the available evidence. Duration of Corticosteroid Administration Level 3 Corticosteroids, if given, should be tapered slowly over a 2 week time period, or longer in symptomatic patients, based upon an individualized treatment regimen and a full understanding of the long-term sequelae of corticosteroid therapy. Given the very limited number of studies (two) which met the eligibility criteria for the systematic review, these are the only recommendations that can be offered based on this methodology. Please see "Discussion" and "Summary" section for additional details.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-009-0057-4

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 363

Metadata

Authors
Ryken, T. C., McDermott, M., Robinson, P. D., Ammirati, M., Andrews, D. W., Asher, A. L., Burri, S. H., Cobbs, C. S., Gaspar, L. E., Kondziolka, D., Linskey, M. E., Loeffler, J. S., Mehta, M. P., Mikkelsen, T., Olson, J. J., Paleologos, N. A., Patchell, R. A., & Kalkanis, S. N.
Venue
Journal of Neuro-Oncology
Published
2009-12-03
Volume
96
Issue
1
Pages
103-114
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2002056663
Cited by
363
References
12
FWCI
1.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. https://app.cochat.ai/papers/10.1007/s11060-009-0057-4
The paper
Ryken, T. C., McDermott, M., Robinson, P. D., Ammirati, M., Andrews, D. W., Asher, A. L., Burri, S. H., Cobbs, C. S., Gaspar, L. E., Kondziolka, D., Linskey, M. E., Loeffler, J. S., Mehta, M. P., Mikkelsen, T., Olson, J. J., Paleologos, N. A., Patchell, R. A., & Kalkanis, S. N. (2010). The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-009-0057-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.